Lilly names Fuchs inaugural chief AI officer
Plus: Turnstone restructures and Glycomine appoints a new chairperson
Eli Lilly and Co. (NYSE:LLY) named Thomas Fuchs chief AI officer, the company’s first, effective Oct. 21. Fuchs was the dean and inaugural department chair for AI and human health, director of the Hasso Plattner Institute for digital health, and professor for AI and computational pathology at the Icahn School of Medicine at Mount Sinai.
Turnstone Biologics Corp. (NASDAQ:TSBX) announced several changes to its executive team as it restructures to focus on Phase I program TIDAL-01 to treat solid tumors, and reduces its headcount by about 60%. The company promoted veterans Saryah Azmat from CBO to COO, and Michael Fitch from VP to SVP of manufacturing. Turnstone appointed SVP of Clinical Development Ines Verdon to lead clinical development following the retirement of interim CMO Michael Burgess on Nov. 1. VP of Finance Wendy Worcester will become principal financial and accounting officer on Oct. 25, when CFO Venkat Ramanan departs. Also leaving is interim CTO Vijay Chiruvolu, on Nov. 1. Both Ramanan and Chiruvolu will become company advisers; Burgess will remain a board member. ...